Imagion Biosystems Ltd.

As of December 31, 2025, Imagion Biosystems Ltd. carries a market capitalization of 12.19M, placing it among publicly traded companies globally. Its enterprise value stands at 12.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Imagion Biosystems Ltd. has 487.54M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Imagion Biosystems Ltd. maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -118.62, indicating conservative leverage, while an interest coverage ratio of -4.24 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -177.79, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Imagion Biosystems Ltd.'s stock has declined approximately 81.48% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

These figures cover the twelve months ended December 31, 2025. EBITDA reached -3.58M, while operating income came in at -3.58M.

As of December 31, 2025, Imagion Biosystems Ltd. holds 1.85M in cash and equivalents against 2.56M in total debt, resulting in a net debt position of 680,295.00. Total book value stands at -2.16M, with working capital of -2.17M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -26.60, meaning Imagion Biosystems Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Imagion Biosystems Ltd.'s most recent stock split took place on November 27, 2023 with a 40:1 split ratio.